Tuberculosis (TB) is a leading infectious cause of death in developing countries. Control of TB has been undermined by changing demographic patterns and the HIV epidemic. The World Health Organization has endorsed directly observed therapy, short course (DOTS) as the principal strategy for controlling TB worldwide. Accumulating evidence suggests the DOTS strategy will be insufficient to produce a reduction in TB incidence and will result in continued high rates of TB deaths for at least a decade. Molecular epidemiologic data suggest that up to one-third of TB in both developing and comprehensive TB control strategies may be more efficacious in controlling the disease.
The aim of this study is to conduct a randomized, community trial of alternative strategies to control TB in a developing country with high rates of TB and endemic HIV. Two communities in Rio de Janeiro with similar TB epidemiology have been selected for the trial. In one community, DOTS+ will be used, incorporating DOTS for TB and active outreach to evaluate household contacts and routine multiproject proposal, a randomized trial of weekly rifapentine and isoniazid versus twice weekly rifampin and pyrazinamide study will be the community incidence of TB after four years of intervention and the molecular epidemiologic patterns of TB isolates in the two communities. We hypothesize that DOTS+ will result in an initial increase in TB rate as a result of case finding, but after four years will produce lower case rates than DOTS alone. We also hypothesize that DOTS+ will result in less clonal clustering of TB isolates after four years than DOTS alone, with fewer isolates in clusters and smaller cluster sizes. This innovative strategy for controlling TB in a high-incidence setting will provide important information for TB control strategies worldwide.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI045432-04
Application #
6651240
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2002-09-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Conde, Marcus B; Mello, Fernanda C Q; Duarte, Rafael Silva et al. (2016) A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One 11:e0154778
Miller, A C; Golub, J E; Cavalcante, S C et al. (2010) Controlled trial of active tuberculosis case finding in a Brazilian favela. Int J Tuberc Lung Dis 14:720-6
Cavalcante, S C; Durovni, B; Barnes, G L et al. (2010) Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 14:203-9
Pacheco, Antonio G; Durovni, Betina; Cavalcante, Solange C et al. (2008) AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS One 3:e3132
Guerra, Renata L; Hooper, Nancy M; Baker, James F et al. (2008) Cost-effectiveness of different strategies for amplified Mycobacterium tuberculosis direct testing for cases of pulmonary tuberculosis. J Clin Microbiol 46:3811-2
Dooley, Kelly; Flexner, Charles; Hackman, Judith et al. (2008) Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 52:4037-42
Guerra, Renata L; Baker, James F; Alborz, Roya et al. (2008) Specimen dilution improves sensitivity of the amplified Mycobacterium tuberculosis direct test for smear microscopy-positive respiratory specimens. J Clin Microbiol 46:314-6
Arias, Mayra; Mello, Fernanda C Q; Pavon, Ada et al. (2007) Clinical evaluation of the microscopic-observation drug-susceptibility assay for detection of tuberculosis. Clin Infect Dis 44:674-80
Guerra, Renata L; Hooper, Nancy M; Baker, James F et al. (2007) Use of the amplified mycobacterium tuberculosis direct test in a public health laboratory: test performance and impact on clinical care. Chest 132:946-51
Tavares, Ricardo C Oliveira; Salgado, Jorge; Moreira, Valeria Barbosa et al. (2007) Interferon gamma response to combinations 38 kDa/CFP-10, 38 kDa/MPT-64, ESAT-6/MPT-64 and ESAT-6/CFP-10, each related to a single recombinant protein of Mycobacterium tuberculosis in individuals from tuberculosis endemic areas. Microbiol Immunol 51:289-96

Showing the most recent 10 out of 29 publications